<DOC>
	<DOCNO>NCT00808002</DOCNO>
	<brief_summary>The intensification maraviroc recently HIV-1-infected patient preferred gold-standard triple therapy compose raltegravir plus tenofovir/emtricitabine could accelerate decay HIV-1 reservoir latently infect cell establish early HIV-1 infection . This could provide insight area , decrease size latent reservoir , translate clinical benefit patient .</brief_summary>
	<brief_title>Efficacy Treatment Intensification With Maraviroc HIV-1 Viral Latency Recently Infected Hiv-1 na√Øve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine</brief_title>
	<detailed_description>A reservoir latently infect cell establish early infection may involve maintenance viral persistence despite continuous highly active antiretroviral therapy ( HAART ) . This likely represent major barrier virus eradication patient successful combination antiretroviral therapy . The majority viruses latent reservoir use CCR5 receptor entry . More recently , clear evidence decay HIV-1 reservoir patient initiated antiretroviral therapy early infection demonstrate . The treatment acute infection may set stage subsequent attempt eradication . To achieve , potent antiretroviral therapy and/or potent antilatency therapy may need . In contrast previous antiretroviral drug , maraviroc need cross cell membrane , require intracellular processing order exert activity . In addition , cross-resistance entry inhibitor agent act intracellular target . Maraviroc demonstrate potent antiviral activity CCR5-tropic HIV-1 virus test . Maraviroc could thus fulfil requirement optimal candidate treatment intensification HIV-1 infect patient recent HIV-1 infection .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1 . HIV1 infect adult ( &gt; =18 year old ) . 2 . No previous antiretroviral therapy 2 week . 3 . HIV1 infection document past 6 month previous negative ELISA test , document clinical acute seroconversion past 6 month . 4 . CCR5tropism confirm screen . 5 . Voluntary write informed consent . 1 . Pregnancy fertile woman willing pregnant . 2 . Active substance abuse major psychiatric disease . 3 . Presence NRTI mutation screen genotype .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Maraviroc</keyword>
	<keyword>CCR5 antagonist</keyword>
	<keyword>Primary HIV Infection</keyword>
	<keyword>HIV-1 reservoir</keyword>
	<keyword>eradication</keyword>
	<keyword>treatment naive</keyword>
</DOC>